Holen Sie sich die Stockscreener-App
73.60
1.18%
-0.88
Vorhandelsmarkt:
73.16
-0.44
-0.60%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$74.48
Offen:
$74.7
24-Stunden-Volumen:
2.95M
Relative Volume:
0.63
Marktkapitalisierung:
$228.26B
Einnahmen:
$56.50B
Nettoeinkommen (Verlust:
$8.30B
KGV:
27.72
EPS:
2.655
Netto-Cashflow:
$8.18B
1W Leistung:
-3.90%
1M Leistung:
+5.98%
6M Leistung:
+1.71%
1J Leistung:
-7.13%
1-Tages-Spanne:
$73.42
$75.10
1-Wochen-Bereich:
$73.03
$75.64
52-Wochen-Spanne:
$61.24
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
73.60 | 230.92B | 56.50B | 8.30B | 8.18B | 2.655 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
AstraZeneca’s Olaparib Study: Promising Update for Ovarian Cancer Treatment - TipRanks
Collaborating to innovate: AstraZeneca's collaborations in mRNAs, antisense oligos and cell therapy - BioXconomy
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire Inc.
AstraZeneca, Sanofi Fail to Escape Drugmaker Conspiracy Claims - Bloomberg Law News
AstraZeneca’s Ongoing Study on Ovarian Cancer: Key Insights for Investors - TipRanks
AstraZeneca’s Promising NASH Treatment Study: Key Insights for Investors - TipRanks
AstraZeneca’s New Study on Trastuzumab Deruxtecan: A Potential Game-Changer in Cancer Treatment - TipRanks
AstraZeneca’s New Trial: A Potential Breakthrough for Eosinophilic Diseases in Children - TipRanks
AstraZeneca’s Anifrolumab Study: Real-world Insights into SLE Treatment - TipRanks
Ex-Dividend Reminder: AstraZeneca, Charles Schwab and Brookline Bancorp - Nasdaq
AUGUST 11 DEADLINE: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
AstraZeneca’s New Phase III Trial Targets Unresectable Pleural Mesothelioma - TipRanks
AstraZeneca’s Latest Clinical Study: Evaluating AZD5004’s Impact on Drug Interactions - TipRanks
AstraZeneca’s Ongoing Study on Olaparib for Advanced Ovarian Cancer: Market Implications - TipRanks
AstraZeneca’s Promising Phase II Study on AZD6234 for Diabetes Management - TipRanks
AstraZeneca’s Koselugo Study: Real-World Insights from Korea - TipRanks
AstraZeneca’s Andexanet Alfa Study: Real-World Insights and Market Implications - TipRanks
AstraZeneca’s TITANium Study: A New Hope for B-Cell Malignancies - TipRanks
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes - Financial Times
Swedish Stocks in North America – AstraZeneca Rises 0.8 Percent - MarketScreener
Is Now a Good Time to Reenter AstraZeneca PLC Depositary ReceiptMarket Momentum and Signal Alerts Suggest Reversal - beatles.ru
AstraZeneca’s Phase 3 Trial Update: Potential Game-Changer in Breast Cancer Treatment? - TipRanks
AstraZeneca’s Promising Study on AZD9829 for Blood Cancers: Key Insights for Investors - TipRanks
AstraZeneca’s Olaparib Study: A Potential Game-Changer in Breast Cancer Treatment - TipRanks
AstraZeneca’s New Study on HER2 Expression in Gynecological Cancers: What Investors Need to Know - TipRanks
AstraZeneca’s Tagrisso Mountain Grows, But The Climb Will Be Challenging - insights.citeline.com
AstraZeneca PLC Depositary Receipt Breaks Below Key Support LevelRisk Controlled Picks With Real Returns Outlined - beatles.ru
What makes AstraZeneca PLC Depositary Receipt stock price move sharplyOutstanding growth strategies - Jammu Links News
Is it the right time to buy AstraZeneca PLC Depositary Receipt stockBreakthrough wealth creation - Jammu Links News
AstraZeneca’s Latest Study on Asthma Inhalers: Key Insights for Investors - TipRanks
What are AstraZeneca PLC Depositary Receipt company’s key revenue driversMassive stock growth - Jammu Links News
How strong is AstraZeneca PLC Depositary Receipt company’s balance sheetGet timely advice on market trends - Jammu Links News
What is the risk reward ratio of investing in AstraZeneca PLC Depositary Receipt stockOutstanding yields - jammulinksnews.com
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca’s AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension - The Globe and Mail
Goldman Sachs Maintains ASTRAZENECA PLC(AZNCF.US) With Buy Rating, Cuts Target Price to $189.77 - 富途牛牛
Proactive weekly health highlights: AstraZeneca, GSK, hVIVO, Avacta, and more - Proactive financial news
AstraZeneca (AZN) Bets Big on U.S. with $50 Billion Manufacturing Expansion - MSN
AstraZeneca’s Oral Drug Revolution: Could This Be the Future of Heart & Lung Treatments? - Smartkarma
AstraZeneca Can't Take Diabetes Drug IP Appeal To Top Court - Law360
AstraZeneca reports total voting rights of 1.55 billion ordinary shares - Investing.com
AstraZeneca’s New Study on Endometrial Cancer Treatment: Key Insights for Investors - TipRanks
AstraZeneca’s AZD5004: A New Hope for Obesity and Overweight Management - TipRanks
AstraZeneca’s Ongoing Study on New Breast Cancer Treatment Shows Promise - TipRanks
AstraZeneca’s PRIMROSE Study: A New Frontier in Cancer Treatment - TipRanks
AstraZeneca’s New Heart Failure Study: Potential Market Impact - TipRanks
AstraZeneca’s Promising Study on Advanced Cancer Treatments: A Market Overview - TipRanks
AstraZeneca’s Ongoing Study on Olaparib: Potential Market Implications - The Globe and Mail
AstraZeneca’s LYNPARZA Study: Monitoring Safety in Breast Cancer Treatment - The Globe and Mail
AstraZeneca’s Calquence Study: Ensuring Safety in Real-World Use - The Globe and Mail
AstraZeneca’s New COPD Study: Potential Market Impact - The Globe and Mail
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):